Biogen

Youtube Subscribe

Open: 299.77 Close: 297.83 Change: -1.94

What an AI found about Biogen after reading the whole Internet.

This document will help you to evaluate Biogen without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Biogen are: Biogen, FDA, drug, Alzheimers, approval, stock, BIIB, and the …

Concept Map

Semantic Network

Stock Summary

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, AVonEX, PLE.

Today's Summary

Biogen Inc. last traded at just under $309, where they closed Thursday. FDA AdCom has unanimously voted in favour of Biogen and Eisais Leqembi in Alzheimers disease. FDA granted accelerated approval at the start of the year, the verdict boosts the drugs full approval.

Today's News

Biogen Inc. last traded at just under $309, where they closed Thursday. The decline in Biogen revenue in recent years can primarily be attributed to generic competition for its multiple sclerosis drug Tecfidera. FDA advisers vote in favor of Biogen and Eisais collaborative Alzheimers treatment. FDA advisory committee votes in favor. Biogen stock halted for news pending. Biogen Inc (BIIB) stock price today, quote, latest discussions, interactive chart and news. Biogen CEO calls new Alzheimers drug first breach of diseases ‘fortress wall’ Biogen Inc. (BIIB) latest stock news & headlines - yahoo finance. biogen inc. (biib) latest. stock news and headlines. Biogen surges as FDA panel gives final nod to Alzheimers treatment. UBS completes takeover of Credit Suisse and Biogen wins key FDA support for its Alzheimers drug. Oracle set for new record high ahead of Q4 earnings and Silvio Berlusconi dies at 86. Biogen Inc. (NASDAQ: BIIB) announced several changes to its Board of Directors today. FDA panel unanimously recommends Biogen (BIIB) alzheimers drug for approval. Analyst Consensus: Strong Buy Stock Forecasts. FDA panel greenlights Biogens Leqembi Latis drug for approval. FDA panel to debate US approval for Alzheimers drug from Eisai and Biogen. Biogen has raised $80M  over 1 round. FDA AdCom has unanimously voted in favour of Biogen and Eisais Leqembi in Alzheimers disease. FDA granted accelerated approval at the start of the year, the verdict boosts the drugs full approval prospects. Biogen Announces Changes to Its Board of Directors. Biogen said biotech exec Susan Langer was nominated to its board. Langer worked for Biogen in roles of increasing responsibility. Biogen (NASDAQ: BIIB ) stock is a hot topic among traders on Monday as the companys shares resumed trading following a halt that was in effect on Friday. An FDA committee is voting in favor of approving Biogens Alzheimers drug. If the FDA moves forward with approval for this Alzheimer treatment, it could result in increased revenue and earnings for Biogen.

Stock Profile

"Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts."

Keywords

The game is changing. There is a new strategy to evaluate Biogen fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Biogen are: Biogen, FDA, drug, Alzheimers, approval, stock, BIIB, and the most common words in the summary are: biogen, stock, market, alzheimers, drug, news, top, . One of the sentences in the summary was: FDA AdCom has unanimously voted in favour of Biogen and Eisais Leqembi in Alzheimers disease. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #biogen #stock #market #alzheimers #drug #news #top.

Read more →

Youtube Subscribe

---